MedPath
Found 4 clinical trials|View Analysis
Sort by:

TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients

Phase 2
Not yet recruiting
Conditions
Chronic Myeloid Leukemia
Accelerated Phase CML
Interventions
Drug: TGRX-678
First Posted Date
2024-06-12
Last Posted Date
2024-06-12
Lead Sponsor
Shenzhen TargetRx, Inc.
Target Recruit Count
40
Registration Number
NCT06453902
Locations
🇨🇳

Peking University People's Hospital, Beijing, Beijing, China

SARS-CoV-2 Donor-Recipient Immunity Transfer

Completed
Conditions
Acute Lymphoblastic Leukemia
Hematopoietic and Lymphoid Cell Neoplasm
Hodgkin Lymphoma
Acute Myeloid Leukemia
Chronic Phase CML, BCR-ABL1 Positive
Lymphoblastic Lymphoma
COVID-19 Infection
Myelodysplastic Syndrome
Non-Hodgkin Lymphoma
Accelerated Phase CML, BCR-ABL1 Positive
Interventions
Procedure: Biospecimen Collection
Other: Diagnostic Laboratory Biomarker Analysis
Other: Electronic Health Record Review
Other: Questionnaire Administration
First Posted Date
2020-12-14
Last Posted Date
2024-04-08
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
26
Registration Number
NCT04666025
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant

Phase 1
Active, not recruiting
Conditions
Chronic Phase CML, BCR-ABL1 Positive
Hematopoietic Cell Transplant Recipient
Hodgkin Lymphoma
Myelodysplastic Syndrome
Non-Hodgkin Lymphoma
Myelofibrosis
Hematopoietic and Lymphoid Cell Neoplasm
Donor
Myelodysplastic/Myeloproliferative Neoplasm
Acute Myeloid Leukemia in Remission
Interventions
Biological: Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
First Posted Date
2018-06-18
Last Posted Date
2024-07-12
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
34
Registration Number
NCT03560752
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies

Phase 1
Withdrawn
Conditions
Ph+ Acute Lymphoblastic Leukemia (Ph+ALL)
Ph- Acute Lymphoblastic Leukemia (Ph-ALL)
Chronic Myeloid Leukemia Accelerated Phase (CML-AP, Ph+)
Chronic Myeloid Leukemia Blast Crisis (CML-BC, Ph+)
Interventions
Drug: ETC-1907206
Drug: dasatinib
First Posted Date
2018-01-30
Last Posted Date
2018-10-25
Lead Sponsor
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
Registration Number
NCT03414450
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

🇺🇸

Winship Cancer Institute, Emory University, Atlanta, Georgia, United States

🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 3 locations
© Copyright 2025. All Rights Reserved by MedPath